V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330012454 | 330005377 | null | null | Curative (C) | 2014-06-05 | 2014-07-03 | AFATINIB | N | N | 330019906 | CISPLATIN + GEMCITABINE |
| 330012455 | 330005383 | 1.49 | 12.5 | Curative (C) | 2013-03-14 | 2014-01-18 | MAP + MIFAMURTIDE | N | N | 330019921 | EMA |
| 330012456 | 330010843 | null | 68 | Palliative (P) | 2014-01-14 | 2014-01-21 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN | N | null | 330019979 | CAPE + CARBOPLATIN + CETUXIMAB |
| 330012457 | 330005390 | 1.79 | 44 | Curative (C) | 2016-03-27 | 2016-03-28 | Doxorubicin + Ifosfamide | 01 | N | 330020045 | EC |
| 330012458 | 330005403 | 0 | 63.6 | Palliative (P) | 2018-05-20 | 2018-05-21 | CAPECITABINE + OXALIPLATIN | N | N | 330020153 | CYTARABINE |
| 330012459 | 330008945 | null | 20.6 | null | null | 2015-05-28 | IMATINIB | null | null | 330020179 | AML17 TRIAL |
| 330012460 | 330005409 | 0 | null | Neo-adjuvant (N) | 2017-02-07 | 2017-02-11 | STS Rhabdo RMS 2005 Vin Cyclo | N | Y | 330020208 | ICE |
| 330012461 | 330011907 | null | null | Palliative (P) | null | 2015-08-25 | Cyclophosphamide High Dose | N | null | 330020236 | CISPLATIN + DOXORUBICIN + METHOTREXATE |
| 330012462 | 330005416 | null | 49.3 | Palliative (P) | null | 2016-09-13 | PCV | null | null | 330020254 | IVA |
| 330012464 | 330005441 | null | null | Palliative (P) | 2018-04-24 | 2018-04-26 | Carboplatin + Pemetrexed | 2 | N | 330020433 | DOXORUBICIN + GEMCITABINE |
| 330012465 | 330005444 | 1.76 | 78.2 | Curative (C) | 2019-04-01 | 2019-04-02 | Cyclophosphamide High Dose | 2 | Y | 330020457 | POMB/ACE |
| 330012466 | 330005452 | 1.65 | null | Palliative (P) | 2015-12-23 | 2016-01-04 | IMATINIB | N | N | 330020527 | CYCLOPHOSPHAMIDE + DOXORUBICIN + ETOPOSIDE + VINCRISTINE |
| 330012467 | 330005454 | 1.85 | 90 | Curative (C) | 2013-11-11 | 2013-11-11 | STS Rhabdomyosarcoma RMS 2005 IVA | N | N | 330020552 | CAPECITABINE + CISPLATIN |
| 330012468 | 330005458 | 1.6 | 78.8 | Palliative (P) | 2014-05-22 | 2015-03-10 | Capecitabine + Streptozocin | 02 | N | 330020565 | UKALL2014 |
| 330012469 | 330005462 | 1.83 | 86 | Neo-adjuvant (N) | 2019-03-16 | 2019-03-20 | Cyclophosphamide+Fludara+TBI Allo | 01 | N | 330020590 | VIDE |
| 330012470 | 330005465 | 1.69 | 45.1 | Curative (C) | 2017-11-14 | 2017-11-20 | Ifosfamide 3g/m2 5 day | 02 | N | 330020602 | MIDOSTAURIN |
| 330012471 | 330005469 | 0 | 67 | Palliative (P) | 2014-01-06 | 2014-01-06 | ATG + Busulfan + Fludarabine | 02 | N | 330020635 | CARBO + THIOTEPA + TOPOTECAN |
| 330012472 | 330005472 | 1.69 | null | Palliative (P) | 2017-03-23 | 2017-04-23 | VeIP | N | N | 330020665 | HYDROXYCARBAMIDE |
| 330012474 | 330005483 | 1.76 | 58.6 | Neo-adjuvant (N) | 2017-10-09 | 2017-10-16 | POMALIDOMIDE | 02 | N | 330020710 | IPO |
| 330012475 | 330005497 | 1.71 | null | Adjuvant (A) | 2014-05-15 | 2014-05-26 | ALL UKALL2011 Maintenance A2 | 2 | N | 330020832 | OXALIPLATIN + MDG |
| 330012476 | 330005503 | 1.85 | 66.6 | Curative (C) | null | 2018-08-29 | Alemtuz+Fludara+Melphalan RIC MUD | N | N | 330020902 | CISPLATIN + FLUOROURACIL + RT |
| 330012477 | 330009004 | 1.77 | 78.25 | Palliative (P) | 2015-12-18 | 2016-02-15 | CYCLOPHOSPHAMIDE + DOXORUBICIN + ETOPOSIDE + VINCRISTINE | N | N | 330020977 | IFOSFAMIDE + VINCRISTINE |
| 330012478 | 330005516 | 0 | 71.5 | null | 2014-09-04 | 2014-09-07 | CISPLATIN + CYCLO + DOXORUBICIN | 2 | N | 330020998 | GEMCITABINE + PACLITAXEL |
| 330012479 | 330005517 | null | 22.6 | Curative (C) | 2014-12-24 | 2014-12-27 | Hydroxycarbamide | 02 | N | 330021007 | IBRUTINIB |
| 330012481 | 330005527 | null | 49.4 | Curative (C) | 2014-09-26 | 2014-09-26 | STREPTOZOCIN | N | N | 330021093 | AML19 TRIAL |
| 330012483 | 330009020 | null | null | Palliative (P) | 2017-07-15 | 2017-07-15 | DHAP | Y | N | 330021120 | EMA/CO |
| 330012484 | 330005546 | 1.56 | 55 | Palliative (P) | 2016-08-20 | 2017-02-06 | UKALL14- Intens/CNS Proph | N | N | 330021212 | BEVACIZUMAB + TEMOZOLOMIDE |
| 330012485 | 330005550 | null | 75 | Curative (C) | null | 2016-10-29 | CISPLATIN + CYCLO + DOXORUBICIN | N | N | 330021284 | GEMCITABINE |
| 330012486 | 330005555 | 1.74 | 60.8 | Curative (C) | 2015-12-08 | 2015-12-08 | Clofarabine + Cytarabine | N | N | 330021301 | CYCLOPHOSPHAMIDE HIGH DOSE |
| 330012487 | 330005556 | 1.64 | 72 | Palliative (P) | 2014-07-18 | 2014-07-19 | Gemcitabine 1000mg/m2 D1 8 15 | 02 | N | 330021309 | VINCRISTINE |
| 330012488 | 330005565 | 1.73 | 84.7 | Palliative (P) | 2016-01-04 | 2016-06-18 | BEP 3 day | 2 | N | 330021342 | CHLORAMBUCIL + RITUXIMAB |
| 330012489 | 330009038 | 1.76 | 90.5 | Curative (C) | 2017-12-20 | 2017-12-20 | FLAG | 02 | N | 330021349 | AML19 TRIAL |
| 330012490 | 330005573 | 1.77 | 74 | Palliative (P) | 2016-12-26 | 2016-12-28 | Hydroxycarbamide | N | N | 330021390 | IVA |
| 330012491 | 330005576 | 1.82 | null | Palliative (P) | 2016-01-25 | 2016-02-25 | Bortezomib +/- Dexamethasone | N | N | 330021428 | CARBOPLATIN + CETUXIMAB + FU |
| 330012492 | 330005581 | 0 | null | Palliative (P) | null | 2015-07-27 | Doxorubicin + Olaratumab | N | N | 330021489 | CYCLOPHOSPHAMIDE + VINCRISTINE |
| 330012493 | 330005582 | 1.6 | 69.9 | Palliative (P) | 2017-01-16 | 2017-01-16 | CARBO + THIOTEPA + TOPOTECAN | 02 | N | 330021497 | CISPLATIN + DOXORUBICIN + ETOPOSIDE |
| 330012494 | 330005592 | 1.63 | null | Palliative (P) | 2014-03-29 | 2014-03-29 | EP | 02 | null | 330021602 | DOXORUBICIN + IFOSFAMIDE |
| 330012495 | 330005598 | 1.83 | null | Curative (C) | 2016-06-11 | 2016-10-12 | Capecitabine (21days) + Carboplatin | 02 | N | 330021653 | CAPECITABINE + CISPLATIN |
| 330012496 | 330005602 | 0 | 0 | Curative (C) | 2017-10-02 | 2017-10-08 | BCG Intravesical | N | N | 330021660 | BCG |
| 330012497 | 330005612 | 1.58 | null | Palliative (P) | 2014-10-17 | 2014-10-18 | CYTARABINE | 2 | N | 330021734 | IPILIMUMAB |
| 330012498 | 330005621 | 1.83 | null | Adjuvant (A) | 2016-09-10 | 2016-09-26 | CETUXIMAB + CISPLATIN + FU | N | N | 330021850 | IMATINIB |
| 330012499 | 330005628 | 1.78 | 53.5 | Curative (C) | 2015-09-08 | 2015-09-08 | LIPOSOMAL DAUNORUBICIN | N | null | 330022010 | EP |
| 330012500 | 330005637 | 1.73 | 68.7 | Curative (C) | 2018-11-24 | 2019-03-12 | RUXOLITINIB | N | N | 330022152 | AML19 TRIAL |
| 330012501 | 330005642 | 1.66 | 93.9 | Palliative (P) | 2017-11-05 | 2017-12-17 | Ipilimumab | N | N | 330022242 | DASATINIB |
| 330012502 | 330005649 | 0 | 23.9 | Palliative (P) | null | 2017-01-30 | CYCLOPHOSPHAMIDE + DOXORUBICIN + ETOPOSIDE + VINCRISTINE | N | N | 330022302 | HYDROXYCARBAMIDE |
| 330012503 | 330005652 | 1.61 | 67.8 | Palliative (P) | null | 2016-02-12 | Bendamustine +/- Prednisolone | null | null | 330022329 | MAP + MIFAMURTIDE |
| 330012504 | 330009091 | 1.78 | 76.6 | Neo-adjuvant (N) | 2016-07-19 | 2016-07-19 | CARBOPLATIN + Cetuximab + FLUOROURACIL | 1 | N | 330022493 | DASATINIB |
| 330012505 | 330005670 | 1.68 | 65.4 | Curative (C) | 2015-08-18 | 2015-09-22 | CVD | 2 | N | 330022662 | PEMBROLIZUMAB |
| 330012506 | 330005676 | 1.77 | 82.2 | null | null | 2018-09-05 | STS Rhabdomyosarcoma RMS 2005 VA | N | N | 330022813 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 330012507 | 330005688 | 1.7 | 61.2 | Adjuvant (A) | 2017-07-17 | 2017-07-18 | Cyclophosphamide High Dose | Y | N | 330022926 | CYCLOPHOSPHAMIDE + DACTINOMYCIN + VINCRISTINE |